Hydrophobic penetrating peptide PFVYLI-modified stealth liposomes for doxorubicin delivery in breast cancer therapy

Biomaterials

Volumn 35, Issue 7, 2014, Pages 2283-2294

  Cai, Defu ^a,b,c   Gao, Wei ^b   He, Bing ^b   Dai, Wenbing ^b   Zhang, Hua ^b   Wang, Xueqing ^b   Wang, Jiancheng ^b   Zhang, Xuan ^b   Zhang, Qiang ^b  

^a SHENYANG PHARMACEUTICAL UNIVERSITY   (China)

^b PEKING UNIVERSITY HEALTH SCIENCE CENTER   (China)

^c QIQIHAR MEDICAL UNIVERSITY   (China)

Author keywords

Drug delivery; Hydrophobic penetration peptide; Liposome; Nanomedicine; PFVYLI

Indexed keywords

CELLULAR INTERNALIZATION; DRUG DELIVERY SYSTEM; HYDROPHOBIC INTERACTIONS; INTRACELLULAR DELIVERY; PFVYLI; PHYSICOCHEMICAL CHARACTERISTICS; RECEPTOR EXPRESSION; TEMPERATURE DEPENDENT;

CELL MEMBRANES; CYTOLOGY; DRUG DELIVERY; DRUG PRODUCTS; HYDROPHOBICITY; MEDICAL NANOTECHNOLOGY; MOLECULAR BIOLOGY; PEPTIDES; SURFACE PLASMON RESONANCE; TUMORS;

LIPOSOMES;

CLATHRIN; DOXORUBICIN; LIPOSOME;

ARTICLE; BREAST CANCER; CANCER INHIBITION; CANCER THERAPY; CARDIOTOXICITY; CELL MEMBRANE; CONFOCAL MICROSCOPY; CYTOTOXICITY; DRUG DELIVERY SYSTEM; DRUG RELEASE; ENDOCYTOSIS; IN VITRO STUDY; INTERNALIZATION; LIPID RAFT; PARTICLE SIZE; PRIORITY JOURNAL; SURFACE PLASMON RESONANCE; SYNTHESIS; TISSUE DISTRIBUTION; ZETA POTENTIAL;

DRUG DELIVERY; HYDROPHOBIC PENETRATION PEPTIDE; LIPOSOME; NANOMEDICINE; PFVYLI;

AMINO ACID SEQUENCE; ANIMALS; ANTIBIOTICS, ANTINEOPLASTIC; BREAST NEOPLASMS; CELL LINE, TUMOR; DOXORUBICIN; DRUG CARRIERS; ENDOCYTOSIS; FEMALE; HUMANS; HYDROPHOBIC AND HYDROPHILIC INTERACTIONS; LIPOSOMES; MICE; MICE, INBRED BALB C; MICROSCOPY, CONFOCAL; MOLECULAR SEQUENCE DATA; OLIGOPEPTIDES; SURFACE PLASMON RESONANCE;

EID: 84891373370     PISSN: 01429612     EISSN: 18785905     Source Type: Journal    
DOI: 10.1016/j.biomaterials.2013.11.088     Document Type: Article

References (48)

1. Bonotto M., Bozza C., Di Loreto C., Osa E.O.O., Poletto E., Puglisi F. Making capecitabine targeted therapy for breast cancer: which is the role of thymidine phosphorylase ?. Clin Breast Cancer 2013, 13:167-172.
2. Siegel R., Naishadham D., Jemal A. Cancer statistics, 2012. CA Cancer J Clin 2012, 62:10-29.
3. Ma X., Zhou J., Zhang C.X., Li X.Y., Li N., Ju R.J., et al. Modulation of drug-resistant membrane and apoptosis proteins of breast cancer stem cells by targeting berberine liposomes. Biomaterials 2013, 34:4452-4465.
4. Steinherz L.J., Steinherz P.G., Tan C.T., Heller G., Murphy M.L. Cardiac toxicity 4 to 20 years after completing anthracycline therapy. JAm Med Assoc 1991, 266:1672-1677.
5. Carvalho C., Santos R.X., Cardoso S., Correia S., Oliveira P.J., Santos M.S., et al. Doxorubicin: the good, the bad and the ugly effect. Curr Med Chem 2009, 16:3267-3285.
6. Ray M.R., Lakshmi C., Deb C., Ray C., Lahiri T. Modulatory effect of dopamine on doxorubicin-induced myelosuppression. Comp Haematol Int 2000, 10:212-220.
7. Farokhzad O.C., Langer R. Impact of nanotechnology on drug delivery. ACS Nano 2009, 3:16-20.
8. Sun M.J., Wang Y., Shen J., Xiao Y.Y., Su Z.G., Ping Q.N. Octreotide-modification enhances the delivery and targeting of doxorubicin-loaded liposomes to somatostatin receptors expressing tumor invitro and invivo. Nanotechnology 2010, 21:475101.
9. She W.C., Li N., Luo K., Guo C.H., Wang G., Geng Y.Y., et al. Dendronized heparin-doxorubicin conjugate based nanoparticle as pH-responsive drug delivery system for cancer therapy. Biomaterials 2013, 34:2252-2264.
10. Xu W.J., Siddiqui I.A., Nihal M., Pilla S., Rosenthal K., Mukhtar H., et al. Aptamer-conjugated and doxorubicin-loaded unimolecular micelles for targeted therapy of prostate cancer. Biomaterials 2013, 34:5244-5253.
11. ®-The first FDA-approved nano-drug: lessons learned. JControl Release 2012, 160:117-134.
12. Ning Y.M., He K., Dagher R., Sridhara R., Farrell A.T., Justice R., et al. Liposomal doxorubicin in combination with bortezomib for relapsed or refractory multiple myeloma. Oncology 2007, 21:1503-1508.
13. Lammers T., Hennink W.E., Storm G. Tumour-targeted nanomedicines: principles and practice. Br J Cancer 2008, 99:392-397.
14. Xiang Y., Liang L., Wang X.Q., Wang J.C., Zhang X., Zhang Q. Chloride channel-mediated brain glioma targeting of chlorotoxin-modified doxorubicine-loaded liposomes. JControl Release 2011, 152:402-410.
15. Xiong X.B., Lu W.L., Zhang X., Zhang H., Nagai T., Zhang Q. Enhanced intracellular delivery and improved antitumor efficacy of doxorubicin by sterically stabilized liposomes modified with a synthetic RGD mimetic. JControl Release 2005, 107:262-275.
16. Duncan R. Polymer conjugates as anticancer nanomedicines. Nat Rev Cancer 2006, 6:688-701.
17. Hevir N., Trost N., Debeljak N., Rizer T.L. Expression of estrogen and progesterone receptors and estrogen metabolizing enzymes in different breast cancer cell lines. Chem Biol Interact 2011, 191:206-216.
18. Parker N., Turk M.J., Westrick E., Lewis J.D., Low P.S., Leamon C.P. Folate receptor expression in carcinomas and normal tissues determined by a quantitative radioligand binding assay. Anal Biochem 2005, 338:284-293.
19. Zhao B.X., Zhao Y., Huang Y., Luo L.M., Song P., Wang X., et al. The efficiency of tumor-specific pH-responsive peptide-modified polymeric micelles containing paclitaxel. Biomaterials 2012, 33:2508-2520.
20. Lammers T., Kiessling F., Hennink W.E., Storm G. Drug targeting to tumors: principles, pitfalls and (pre-) clinical progress. JControl Release 2012, 161:175-187.
21. Jiang T.Y., Zhang Z.H., Zhang Y.L., Lv H.X., Zhou J.P., Li C.C., et al. Dual-functional liposomes based on pH-responsive cell-penetrating peptide and hyaluronic acid for tumor-targeted anticancer drug delivery. Biomaterials 2012, 33:9246-9258.
22. Mae M., Langel U. Cell-penetrating peptides as vectors for peptide, protein and oligonucleotide delivery. Curr Opin Pharmacol 2006, 6:509-514.
23. Ruan G., Agrawal A., Marcus A.I., Nie S. Imaging and tracking of tat peptideconjugated quantum dots in living cells: new insights into nanoparticle uptake, intracellular transport, and vesicle shedding. JAm Chem Soc 2007, 129:14759-14766.
24. Meade B.R., Dowdy S.F. Exogenous siRNA delivery using peptide transduction domains/cell penetrating peptides. Adv Drug Deliv Rev 2007, 59:134-140.
25. Kanazawa T., Taki H., Tanaka K., Takashima Y., Okada H. Cell-penetrating peptide-modified block copolymer micelles promote direct brain delivery via intranasal administration. Pharm Res 2011, 28:2130-2139.
26. Jones A.T., Sayers E.J. Cell entry of cell penetrating peptides: tales of tails wagging dogs. JControl Release 2012, 161:582-591.
27. Lin Y.Z., Yao S.Y., Veach R.A., Torgerson T.R., Hawiger J. Inhibition of nuclear translocation of transcription factor NF-kappa B by a synthetic peptide containing a cell membrane-permeable motif and nuclear localization sequence. JBiol Chem 1995, 270:14255-14258.
28. Gao C.S., Mao S.L., Ditzel H.J., Farnaes L., Wirsching P., Lerner R.A., et al. Acell-penetrating peptide from a novel pVII-pIX phage-displayed random peptide library. Bioorg Med Chem 2002, 10:4057-4065.
29. Nakayama F., Yasuda T., Umeda S., Asada M., Imamura T., Meineke V., et al. Fibroblast growth factor-12 (FGF12) translocation into intestinal epithelial cells is dependent on a novel cell-penetrating peptide domain. JBiol Chem 2011, 286:25823-25834.
30. Liu X.Y., Timmons S., Lin Y.Z., Hawiger J. Identification of a functionally important sequence in the cytoplasmic tail of integrin beta 3 by using cell-permeable peptide analogs. Proc Natl Acad Sci U S A 1996, 93:11819-11824.
31. Moulton H.M., Nelson M.H., Hatlevig S.A., Reddy M.T., Iversen P.L. Cellular uptake of antisense morpholino oligomers conjugated to arginine-rich peptides. Bioconjug Chem 2004, 15:290-299.
32. Takayama K., Hirose H., Tanaka G., Pujals S., Katayama S., Nakase I., et al. Effect of the attachment of a penetration accelerating sequence and the influence of hydrophobicity on octaarginine-mediated intracellular delivery. Mol Pharm 2012, 9:1222-1230.
33. Rhee M., Davis P. Mechanism of uptake of C105Y, a novel cell-penetrating peptide. JBiol Chem 2006, 281:1233-1240.
34. Watkins C.L., Brennan P., Fegan C., Takayama K., Nakase I., Futaki S., et al. Cellular uptake, distribution and cytotoxicity of the hydrophobic cell penetrating peptide sequence PFVYLI linked to the proapoptotic domain peptide PAD. JControl Release 2009, 140:237-244.
35. Park J.W., Bang E.K., Jeon E.M., Kim B.H. Complexation and conjugation approaches to evaluate siRNA delivery using cationic, hydrophobic and amphiphilic peptides. Org Biomol Chem 2012, 10:96-102.
36. Wang Z.H., Yu Y., Dai W.B., Lu J.K., Cui J.R., Wu H.N., et al. The use of a tumor metastasis targeting peptide to deliver doxorubicin-containing liposomes to highly metastatic cancer. Biomaterials 2012, 33:8451-8460.
37. Gullotti E., Yeo Y. Extracellularly activated nanocarriers: a new paradigm of tumor targeted drug delivery. Mol Pharm 2009, 6:1041-1051.
38. Allen T.M., Cheng W.W., Hare J.I., Laginha K.M. Pharmacokinetics and pharmacodynamics of lipidic nano-particles in cancer. Anticancer Agents Med Chem 2006, 6:513-523.
39. Haran G., Cohen R., Bar L.K., Barenholz Y. Transmembrane ammonium sulfate gradient in liposomes produce efficient and stable entrapment of amphipathic weak bases. Biochim Biophys Acta 1993, 1151:201-215.
40. Düzgüne&scedil N., Nir S. Mechanisms and kinetics of liposome-cell interactions. Adv Drug Deliv Rev 1999, 40:3-18.
41. Yao D., Ehrlich M., Henis Y.I., Leof E.B. Transforming growth factor-beta receptors interact with AP2 by direct binding to beta2 subunit. Mol Biol Cell 2002, 13:4001-4012.
42. Page E., Winterfield J., Goings G., Bastawrous A., Upshaw-Earley J. Water channel proteins in rat cardiac myocyte caveolae: osmolarity-dependent reversible internalization. Am J Physiol 1998, 274:H1988-H2000.
43. Zhao S.S., Dai W.B., He B., Wang J., He Z., Zhang X., et al. Monitoring the transport of polymeric micelles across MDCK cell monolayer and exploring related mechanisms. JControl Release 2012, 158:413-423.
44. Nakase I., Niwa M., Tacheuchi T., Sonomura K., Kawabata N., Koike Y., et al. Cellular uptake of arginine-rich peptides: role for macropinocytosis and actin rearrangement. Mol Ther 2004, 10:1011-1022.
45. Sharma P., Brown S., Walter G., Santra S., Moudgil B. Nanoparticles for bioimaging. Adv Colloid Interface Sci 2006, 123-126:471-485.
46. Lasic D.D. Doxorubicin in sterically stabilized liposomes. Nature 1996, 380:561-562.
47. Manzoor A.A., Lindner L.H., Landon C.D., Park J.Y., Simnick A.J., Dreher M.R., et al. Overcoming limitations in nanoparticle drug delivery: triggered, intravascular release to improve drug penetration into tumors. Cancer Res 2012, 72:5566-5575.
48. Zhang Q.Y., Tang J., Fu L., Ran R., Liu Y.Y., Yuan M.Q., et al. ApH-responsive α-helical cell penetrating peptide-mediated liposomal delivery system. Biomaterials 2013, 34:7980-7993.